Estrogen receptor positive early breast cancer: the long road

Abstract

The risk of recurrence with early estrogen receptor positive breast cancer continues for decades (1). Because of that risk, long-term follow-up (LTFU) from trials of adjuvant endocrine therapy is quite important. The recent report of the BIG 1-98 trial from Ruhstaller and colleagues (2) provides us with another opportunity to view breast cancer through a longer time course.